News | February 28, 2025
Sanofi India declares 8% growth in net sales for Q4-2024
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Standalone profit from operations for Q4-2024 were Rs. 108 crore
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Subscribe To Our Newsletter & Stay Updated
